CompletedPhase 3NCT03358472
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Studying Squamous cell carcinoma of head and neck
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Incyte Corporation
- Principal Investigator
- Mark Jones, MDIncyte Corporation
- Intervention
- Pembrolizumab(drug)
- Enrollment
- 89 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2025
Study locations (30)
- Pacific Cancer Medical Center, Anaheim, California, United States
- UC Davis Comprehensive Cancer Center, Sacramento, California, United States
- St. Joseph Heritage Healthcare, Santa Rosa, California, United States
- University of Colorado Cancer Center, Aurora, Colorado, United States
- Yale Cancer Center, New Haven, Connecticut, United States
- Northwest Georgia Oncology Centers PC, Douglasville, Georgia, United States
- U of Kansas Cancer Center, Westwood, Kansas, United States
- Baptist Health, Louisville, Kentucky, United States
- St. Vincent Healthcare Cancer Ctr, Billings, Montana, United States
- New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States
- Oklahoma Cancer Specialists and Research, Tulsa, Oklahoma, United States
- Providence Portland Med Center, Portland, Oregon, United States
- Huntsman Cancer Institute Univ of Utah, Salt Lake City, Utah, United States
- Viginia Mason Med Ctr, Seattle, Washington, United States
- Chris OBrien Lifehouse, Camperdown, New South Wales, Australia
- +15 more locations on ClinicalTrials.gov
Collaborators
Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03358472 on ClinicalTrials.govOther trials for Squamous cell carcinoma of head and neck
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07333274Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell CarcinomaShandong Cancer Hospital and Institute
- RECRUITINGPHASE3NCT07026474Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCCUniversität des Saarlandes
- RECRUITINGPHASE1NCT07182149A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsNormunity AccelCo, Inc.
- RECRUITINGNANCT07203911Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled TrialTobias Todsen
- RECRUITINGNANCT07180901Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck CancerCentre hospitalier de l'Université de Montréal (CHUM)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415Local Injection Methylene Blue Combined With Radiation in HNSCC PatientsChina Medical University Hospital
- RECRUITINGPHASE2NCT07088211Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCCShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- RECRUITINGPHASE2NCT07040956A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.West China Hospital
See all trials for Squamous cell carcinoma of head and neck →